SCHEMBL24828829

CC[C@H](C)[C@@H]1NC(=O)[C@@H](NC(=O)[C@H](C)NC(C)=O)CSCCC(=O)N2CN3CN(C2)C(=O)CSC[C@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](C)C(N)=O)CSCCC3=O

nearest known ligand 0.73

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	EPHA2	P29317	8/20	0.73

▸	ACE2	Q9BYF1	2/20	0.63

▸	ACE	P12821	1/20	0.63

▸	NECTIN4	Q96NY8	9/20	0.60

▸	KLKB1	P03952	1/20	0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL24828866	0.99	EPHA2 (0.72)	EPHA2ACE2ACENECTIN4KLKB1
SCHEMBL25819772	0.99	EPHA2 (0.72)	EPHA2ACE2ACENECTIN4KLKB1
SCHEMBL24828848	0.99	EPHA2 (0.72)	EPHA2ACE2ACENECTIN4KLKB1
SCHEMBL24828867	0.99	EPHA2 (0.72)	EPHA2ACE2ACENECTIN4KLKB1
SCHEMBL24828842	0.98	EPHA2 (0.73)	EPHA2ACE2ACENECTIN4KLKB1
SCHEMBL24828838	0.98	EPHA2 (0.73)	EPHA2ACE2ACENECTIN4
SCHEMBL25822715	0.98	EPHA2 (0.70)	EPHA2ACE2ACENECTIN4KLKB1
SCHEMBL24828877	0.98	EPHA2 (0.70)	EPHA2ACE2ACENECTIN4
SCHEMBL24828840	0.97	EPHA2 (0.72)	EPHA2ACE2ACENECTIN4
SCHEMBL25822679	0.97	EPHA2 (0.69)	EPHA2ACE2ACENECTIN4KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230220008-A1	MULTIMERIC BICYCLIC PEPTIDE LIGANDS	BICYCLETX LIMITED (GB)	2023-07-13	—	—	US	disclosed
US-11542304-B2	Multimeric bicyclic peptide ligands	BICYCLETX LIMITED	2023-01-03	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11542304-B2	Multimeric bicyclic peptide ligands	CD40, TNFSF11, TNFRSF9	EPHA2 508/4885ACE2 2341/4885ACE 2512/4885
US-20230220008-A1	MULTIMERIC BICYCLIC PEPTIDE LIGANDS	CD40, TNFSF11, TNFRSF9	EPHA2 508/4885ACE2 2341/4885ACE 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.